(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Atherosclerosis D050197 85 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Steatorrhea D045602 2 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Persian Gulf Syndrome D018923 1 associated lipids
Parasitemia D018512 5 associated lipids
Coronavirus Infections D018352 4 associated lipids
Keratitis, Herpetic D016849 5 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Weight Gain D015430 101 associated lipids
Xanthomatosis D014973 17 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Viremia D014766 4 associated lipids
Tinea Versicolor D014010 5 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Stomach Ulcer D013276 75 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Rosacea D012393 13 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Rasch MR et al. Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. 2012 Langmuir pmid:23033891
Vesikari T et al. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. 2012 Hum Vaccin Immunother pmid:22777094
Bencharitiwong R et al. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. 2012 Hum Vaccin Immunother pmid:22777093
Palma P et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. 2012 Biologicals pmid:22261282
Heikkinen T et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. 2012 Am. J. Obstet. Gynecol. pmid:22939717
Mannino S et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. 2012 Am. J. Epidemiol. pmid:22940713
Klucker MF et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. 2012 J Pharm Sci pmid:22941944
Vishnubhatla S et al. Contact lenses and the rate of evaporation measured in vitro; the influence of wear, squalene and wax. 2012 Cont Lens Anterior Eye pmid:22906863
Hoshino T et al. Lanosterol biosynthesis: the critical role of the methyl-29 group of 2,3-oxidosqualene for the correct folding of this substrate and for the construction of the five-membered D ring. 2012 Chemistry pmid:22933236
Wilson KR et al. The statistical evolution of multiple generations of oxidation products in the photochemical aging of chemically reduced organic aerosol. 2012 Phys Chem Chem Phys pmid:22158973
Xue Z et al. Divergent evolution of oxidosqualene cyclases in plants. 2012 New Phytol. pmid:22150097
Oral E et al. A new mechanism of oxidation in ultrahigh molecular weight polyethylene caused by squalene absorption. 2012 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:22190411
Sancho A et al. More on influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22738111
Yang P et al. Two concise enantioselective total syntheses of (-)-glabrescol implicate alternative biosynthetic pathways starting from squalene. 2012 Org. Lett. pmid:22817611
Calmy A et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. 2012 HIV Med. pmid:22093373
Dell'Era L et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. 2012 Vaccine pmid:22138210
Allain V et al. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. 2012 Nucleic Acids Res. pmid:22075995
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Lokvam J and Fine PV An oxidized squalene derivative from Protium subserratum Engl. (Engl.) growing in Peru. 2012 Molecules pmid:22706374
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Granados-Principal S et al. Squalene ameliorates atherosclerotic lesions through the reduction of CD36 scavenger receptor expression in macrophages. 2012 Mol Nutr Food Res pmid:22648620
Song JY et al. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. 2012 Clin. Vaccine Immunol. pmid:22379067
Caproni E et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. 2012 J. Immunol. pmid:22351935
Kim SK and Karadeniz F Biological importance and applications of squalene and squalane. 2012 Adv. Food Nutr. Res. pmid:22361190
Dey AK et al. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 2012 Vaccine pmid:22366638
Garçon N et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. 2012 Expert Rev Vaccines pmid:22380826
Ramírez-Torres A et al. Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. 2012 J Proteomics pmid:22402057
Tronchoni J et al. Lipid composition of wine strains of Saccharomyces kudriavzevii and Saccharomyces cerevisiae grown at low temperature. 2012 Int. J. Food Microbiol. pmid:22405355
Peric M et al. Electron paramagnetic resonance line shifts and line shape changes due to heisenberg spin exchange and dipole-dipole interactions of nitroxide free radicals in liquids 8. Further experimental and theoretical efforts to separate the effects of the two interactions. 2012 J Phys Chem A pmid:22288424
Liu Y et al. [Researches on influence of squalene synthase gene polymorphism on catalytic efficiency of its encode enzyme in Glycyrrhiza uralensis]. 2012 Zhongguo Zhong Yao Za Zhi pmid:23627178
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498
Binks BP et al. How membrane permeation is affected by donor delivery solvent. 2012 Phys Chem Chem Phys pmid:23073464
Yockel S and Schatz GC Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. 2012 Top Curr Chem pmid:21506003
Dorea JG Safety of thimerosal in vaccines: for whom and how many doses? 2011 Mar-Apr Therapie pmid:23189333
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Fox CB et al. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. 2011 Pharm Dev Technol pmid:20550484
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Puig-Barberà J et al. MF59™-adjuvanted seasonal influenza vaccine in young children. 2011 Expert Rev Vaccines pmid:22043952
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Pollard AJ and Hill AV Antibody repertoire: embracing diversity. 2011 Sci Transl Med pmid:21795586
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Iannazzo S Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. 2011 J Prev Med Hyg pmid:21710816
Seubert A et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21690334
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645